2Spinale FG, Coker ML, Heung LJ, et al. A matric metalloproteinases induction/activation system exists in the human left ventrivular myocardium and is upregulated in heart failure[J]. Circulation Res, 2000,102:1944-1949.
3Torre-Amione G, Kapadia S, Benedict C,et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fracfion: a report from the studies of left ventricular dysfuncfion(SOLVD)[J].J Am Coll Cardiol,1996,27: 1202-1206.
4Tsutamoto T, Hisanaga T, Wada A, et al.Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart fai
5Munger MA, Barbara J, Amber IJ,et al. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy[J]. Am Jcardiol, 1996,77:723-727.
6Hirano H, Yoshida K, Kishimoto T, et al. Continuous activation of gp130, a signaling-transducing receptor component for interleukin-6-related cytokines causes myocardial hypertrophy in mice[J].Proc Natl Acad Sci U.S.A, 1995,92,48622-4866.
7Funakoshi H, Kubota T, kawamura N, et al.Disruption of inducible Nitric Oxide Synthase improvesβ-adrenergic inotropic responsiv-eness but not the survival of mice with cytokineinduced cardiomyopathy[J]. Circ Res,2002,90:959-965.
8Bozkurt B, kribbs SB, clubb FJ, et al. Pathophysiologically relevant concentrations of Tumor Necrosis-alpha promote progrssive left vetricular dysfunction and remodeling in rats[J]. Circulation, 1998,97:1382-1391.
9Li YY , Feng YQ, Kadokami T,et al. Myocardial extracellular matric remodeling in transgenic mice overexpressing tumor necrosis factor-a can be modulated by anti-tumor necrosis factor-a therapy[J]. Proc Natl Acad Sci U.S.A,2000,97:12746-1275.
10Krown KA, Page MT, Nguyen C, et al.Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes;involvement of the sphingolipid signaling cascade in cardiac cell death[J].J Clin Invest, 1996, 98(12):2854-2865.
7Gullestad L,Aukrust P. The cytokine network in heart failure: pathogenetic importance and potential therapeutic targets[J]. Heart Fail Monit, 2001 ; 2( 1 ) : 8-13.
8Parissis JT,Kourea K,Kremastinos D. Anti-cytokine therapies in chronic heart failure:is this concept still alive[J]? Hellenic J Cardiol, 2005 ;46(2) : 101-107.
9Schunkert H, Weinberg EO,Bruckschlegel G, et al. Alteration of growth responses in established cardiac pressure overload hypertrophy in rats with aortic banding[J]. J Clin Invest,1995;96 (6): 2768-2774.
10Tonnessen T,Christensen G,Qie E,et al. Increased cardiac expression of endothelin-1 mRNA in ischemic heart failure in rats [J]. Cardiovascular Res,1997;33(3):601-610.
